Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological...

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Monitoring BCR-ABL1 mutations is vital for managing Philadelphia chromosome-positive leukemias.
• Tyrosine kinase inhibitors (TKIs) are standard treatment, but resistance via BCR-ABL1 mutations necessitates careful patient monitoring.
• Next-generation sequencing (NGS) offers sensitive detection of BCR-ABL1 kinase domain mutations but faces accessibility and cost barriers for routine use.

Purpose of the Study:

• To evaluate alternative methods to NGS for monitoring BCR-ABL1 mutant subclones in chronic myeloid leukemia (CML) patients.
• To compare the efficacy of pyrosequencing, ligation-dependent PCR (LD-PCR), and NGS in detecting and quantifying BCR-ABL1 kinase domain mutations.
• To assess if alternative methods can substitute NGS for routine monitoring of TKI-resistant subclones.

Main Methods:

• Analysis of peripheral blood specimens from CML patients with known BCR-ABL1 kinase domain mutations.
• Comparative assessment of three techniques: pyrosequencing, LD-PCR, and NGS.
• Evaluation of proliferation kinetics of mutant subclones over time during TKI treatment.

Main Results:

• All tested methods (pyrosequencing, LD-PCR, NGS) demonstrated similar trends in the proliferation kinetics of BCR-ABL1 mutant subclones.
• Statistically significant differences in individual specimen results were observed between NGS and the other two methods.
• The study confirmed that different detection methods can be used for monitoring clonal kinetics.

Conclusions:

• Pyrosequencing and LD-PCR are potential alternatives to NGS for monitoring BCR-ABL1 mutant subclones in CML patients.
• Accurate assessment of mutant subclone size requires careful calibration of the chosen detection method.
• Standardization and validation of alternative methods are crucial for reliable clinical implementation in TKI therapy monitoring.